Table 1. Dengue specific monoclonal antibodies.
| Mab | M/H | Binding | Neutralization (W/M/S) | Binding region | Binding DENV serotypes | Ref | |||
|---|---|---|---|---|---|---|---|---|---|
| DV1 | DV2 | DV3 | DV4 | ||||||
| 4G2 | M | F-CR | W. | DII FL | ++ | ++ | +++ | +++ | [35] |
| 3H5 | M | DV2 | S/DV2 | DIII LR | - | +++ | - | - | [36] |
| DV2-46 | M | DV2 | M/DV2 | DI and DII | - | ++ | - | - | [37] |
| DVC-3.7 | H | DV2 | S/DV2 | DIII LR | - | ++ | - | - | [38] |
| 1M7 | H | D-CR | M. | DII | +++ | ++ | +++ | +++ | [39] |
| DVC-10.16 | H | D-C | S. | DIII AS | + | +++ | + | + | [38] |
| 2D22 | H | DV2 | S/DV2 | DI/DII Q | - | ++ | - | - | [40] |
| 8A1 | M | DV3 | S/DV3 | DIII LR | - | - | +++ | - | [41] |
A panel of well-defined mouse or human (M/H) derived Mabs were used to characterize sRecE epitopes. flavivirus cross reactive (F-CR), dengue cross reactive (D-CR), dengue complex (D-C), weakly, moderately or strong (W/M/S) neutralizing, E-domain I, II, III (DI, DII, DIII), fusion loop (FL), lateral ridge (LR), A-strand (AS), quaternary (Q).